Comparing rates of clinically relevant epistaxis in patients taking warfarin versus direct oral anticoagulants.
作者信息
Burke Khristian S, Kong Xiaowen, Haymart Brian, DeCamillo Debbie, Ali Mona, Barnes Geoff, Kaatz Scott
机构信息
Central Michigan University College of Medicine, Jeddo, Michigan, USA.
Department of Internal Medicine, University of Michigan, Frankel Cardiovascular Center, Ann Arbor, Michigan, USA.
出版信息
Res Pract Thromb Haemost. 2024 Nov 20;8(8):102630. doi: 10.1016/j.rpth.2024.102630. eCollection 2024 Nov.
Abstract
摘要
相似文献
1
Comparing rates of clinically relevant epistaxis in patients taking warfarin versus direct oral anticoagulants.比较服用华法林与直接口服抗凝剂的患者发生临床相关鼻出血的比率。
Res Pract Thromb Haemost. 2024 Nov 20;8(8):102630. doi: 10.1016/j.rpth.2024.102630. eCollection 2024 Nov.
2
Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.华法林与直接口服抗凝剂相比，鼻出血发生率更高：一项全国性倾向评分加权研究。
J Intern Med. 2022 Sep;292(3):501-511. doi: 10.1111/joim.13498. Epub 2022 Apr 29.
3
Management and outcome of epistaxis under direct oral anticoagulants: a comparison with warfarin.直接口服抗凝剂相关鼻出血的管理和结局：与华法林的比较。
Int Forum Allergy Rhinol. 2019 Jan;9(1):120-124. doi: 10.1002/alr.22210. Epub 2018 Oct 3.
4
A retrospective review of spontaneous epistaxis outcomes for patients on novel oral anticoagulants compared to antiplatelets and warfarin.一项关于新型口服抗凝剂使用者与抗血小板药物及华法林使用者的自发性鼻出血结局的回顾性研究。
Am J Otolaryngol. 2022 Jul-Aug;43(4):103488. doi: 10.1016/j.amjoto.2022.103488. Epub 2022 May 4.
5
Epistaxis Risk in Patients Treated With Left Atrial Appendage Occlusion Versus Oral Anticoagulation.左心耳封堵术与口服抗凝药治疗患者的鼻出血风险
Laryngoscope. 2025 May;135(5):1636-1641. doi: 10.1002/lary.31949. Epub 2024 Dec 10.
6
Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.抗血栓治疗背景下的鼻出血：Xa因子抑制剂、华法林和抗血小板药物之间的比较。
Laryngoscope. 2019 Jan;129(1):119-123. doi: 10.1002/lary.27400. Epub 2018 Oct 16.
7
Epistaxis Versus Nonepistaxis Bleeding in Anticoagulated Patients With Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial.心房颤动抗凝患者的鼻出血与非鼻出血性出血：ENGAGE AF-TIMI 48试验结果
J Am Heart Assoc. 2025 Jan 21;14(2):e031434. doi: 10.1161/JAHA.123.031434. Epub 2025 Jan 10.
8
Direct oral anticoagulants versus vitamin K antagonists in epistaxis patients: A systematic review and meta-analysis.直接口服抗凝剂与维生素 K 拮抗剂在鼻出血患者中的比较：系统评价和荟萃分析。
Clin Otolaryngol. 2022 Mar;47(2):255-263. doi: 10.1111/coa.13898. Epub 2021 Dec 2.
9
The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis.传统抗凝剂、新型抗凝剂和抗血小板药物对鼻出血的影响。
Laryngoscope. 2021 Sep;131(9):1946-1951. doi: 10.1002/lary.29417. Epub 2021 Feb 3.
10
Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study.直接口服抗凝剂和华法林治疗慢性血栓栓塞性肺动脉高压的长期预后：一项日本前瞻性队列研究。
J Thromb Haemost. 2023 Aug;21(8):2151-2162. doi: 10.1016/j.jtha.2023.03.036. Epub 2023 Apr 10.
本文引用的文献
1
Warfarin is associated with higher rates of epistaxis compared to direct oral anticoagulants: A nationwide propensity score-weighted study.华法林与直接口服抗凝剂相比，鼻出血发生率更高：一项全国性倾向评分加权研究。
J Intern Med. 2022 Sep;292(3):501-511. doi: 10.1111/joim.13498. Epub 2022 Apr 29.
2
Reduction in epistaxis and emergency department visits in patients taking warfarin after implementation of an education program.实施教育项目后，服用华法林的患者鼻出血和急诊就诊减少。
Thromb Res. 2021 Mar;199:119-122. doi: 10.1016/j.thromres.2021.01.007. Epub 2021 Jan 16.
3
Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.抗血栓治疗背景下的鼻出血：Xa因子抑制剂、华法林和抗血小板药物之间的比较。
Laryngoscope. 2019 Jan;129(1):119-123. doi: 10.1002/lary.27400. Epub 2018 Oct 16.
4
Epistaxis in anticoagulated patients: Fewer hospital admissions and shorter hospital stays on rivaroxaban compared to phenprocoumon.抗凝患者的鼻出血：与苯丙香豆素相比，使用利伐沙班的患者住院次数减少且住院时间缩短。
Clin Otolaryngol. 2018 Feb;43(1):103-108. doi: 10.1111/coa.12904. Epub 2017 Jun 5.
5
Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2).膝关节和髋关节置换术后使用华法林预防静脉血栓栓塞：密歇根州抗凝质量改进倡议（MAQI2）的结果。
J Thromb Thrombolysis. 2013 Jan;35(1):10-4. doi: 10.1007/s11239-012-0766-y.
6
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –.利伐沙班与华法林在日本非瓣膜性心房颤动患者中的比较——J-ROCKET AF 研究。
Circ J. 2012;76(9):2104-11. doi: 10.1253/circj.cj-12-0454. Epub 2012 Jun 5.
7
Apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者。
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
8
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
9
Epistaxis in patients taking oral anticoagulant and antiplatelet medication: prospective cohort study.服用口服抗凝药和抗血小板药物患者的鼻出血：前瞻性队列研究。
J Laryngol Otol. 2011 Jan;125(1):38-42. doi: 10.1017/S0022215110001921. Epub 2010 Sep 16.
10
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.非手术患者抗止血药品临床研究中严重出血的定义。
J Thromb Haemost. 2005 Apr;3(4):692-4. doi: 10.1111/j.1538-7836.2005.01204.x.
Zotero 插件